Adipotide vs CJC-1295 with DAC: what the research compares
A comparison of the published research on Adipotide and CJC-1295 with DAC, covering their mechanisms, measured outcomes, and the gaps in the evidence.
Adipotide (also known as FTPP or CKGGRAKDC-GG-D(KLAKLAK)2) is a synthetic peptidomimetic composed of a cyclic targeting sequence linked to a pro-apoptotic peptide. It is not a single-chain peptide but a chimeric molecule: the targeting moiety binds to prohibitin, a protein expressed on the vasculature of white adipose tissue, while the second moiety, a D-amino acid peptide, is designed to disrupt mitochondrial membranes. The compound has a molecular weight of approximately 3.5 kDa, though the evidence block does not provide a precise value. CJC-1295 with DAC (also known as CJC-1295 Drug Affinity Complex) is a tetrasubstituted growth hormone-releasing hormone (GHRH) analogue modified with a maleimidopropionic acid (MPA) linker that enables covalent binding to serum albumin. Its molecular formula and weight are not specified in the evidence block. Both compounds are sold as research chemicals, not approved therapeutics.
The published work on Adipotide centres on the prohibitin-targeted apoptosis of adipose tissue vasculature, while the work on CJC-1295 with DAC centres on the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis via GHRH receptor activation.
Research Studies
Adipotide and targeted apoptosis of white adipose tissue vasculature
Adipotide is a chimeric peptide that combines a cyclic sequence (CKGGRAKDC) that binds to prohibitin on the endothelial cells of white adipose tissue with a D-amino acid sequence (D(KLAKLAK)2) that disrupts mitochondrial membranes. In preclinical models, this targeting was reported to induce apoptosis of the adipose vasculature, leading to rapid resorption of white adipose tissue. The evidence block does not provide specific study results or citations for these preclinical findings, so the details of the model, dose, and outcomes cannot be reported here. The compound is not approved for human use, and no clinical trials are listed in the evidence block.
CJC-1295 with DAC and the GH-IGF-1 axis
CJC-1295 with DAC is a GHRH analogue that acts on the GHRH receptor in the pituitary to stimulate growth hormone release. The DAC modification extends its half-life by binding to albumin. The evidence block cites a review [1] that lists CJC-1295 with DAC among GHRH analogues encountered in clinical practice and online self-administration protocols. The same review notes that these peptides are marketed as "research compounds" and are unregulated. No specific efficacy data for CJC-1295 with DAC are provided in the evidence block beyond its classification.
Adipotide and metabolic outcomes in animal models
The evidence block does not contain any studies reporting metabolic outcomes for Adipotide in animal models. The mechanism of action—targeting prohibitin on adipose vasculature—is described in general terms, but no specific measurements of body weight, fat mass, or metabolic parameters are provided. Therefore, no claims about efficacy can be made from the available evidence.
CJC-1295 with DAC and visceral obesity in HIV patients
A Phase 2 clinical trial [6] evaluated CJC-1295 in HIV patients with visceral obesity. The study was a multicenter, randomized, placebo-controlled, double-blind trial. Patients were treated for 12 weeks with low-dose CJC-1295, high-dose CJC-1295, or placebo, followed by a 6-week follow-up. The objective was to assess efficacy, pharmacokinetics, safety, and tolerability. The evidence block does not report the results of this trial, only its design. This is the only clinical trial listed for CJC-1295 with DAC in the evidence block.
Adipotide and safety profile
The evidence block does not provide any safety data for Adipotide. No studies in humans are listed, and no adverse events are reported. The compound is not approved for any indication, and its safety in humans is unknown.
CJC-1295 with DAC and safety in human trials
The Phase 2 trial [6] included safety and tolerability as objectives, but the evidence block does not report the results. No other safety data for CJC-1295 with DAC are provided. The review [1] notes that these peptides are unregulated and often self-administered, but does not provide specific safety outcomes.
Adipotide and purity in the gray market
A study [2] evaluated the purity, measured abundance, and endotoxin burden of gray market research peptides using a large independent testing dataset. The study included 6441 samples, but the evidence block does not specify whether Adipotide was among them. The study found extensive variability in purity and measured abundance, and compared costs to compounded and FDA-approved alternatives. This finding is relevant to Adipotide as a gray market peptide, but no specific data for Adipotide are given.
CJC-1295 with DAC and purity in the gray market
The same study [2] likely included CJC-1295 with DAC among the tested peptides, but the evidence block does not confirm this. The general finding of variability in purity and abundance applies to the gray market peptide category, which includes CJC-1295 with DAC as noted in [1]. No specific purity data for CJC-1295 with DAC are provided.
Adipotide and regulatory status
Adipotide is not approved by any regulatory agency for human use. The evidence block does not list any clinical trials or regulatory approvals. It is sold as a research chemical.
CJC-1295 with DAC and regulatory status
CJC-1295 with DAC is not approved by the FDA or any other regulatory agency for human use. The Phase 2 trial [6] was conducted in HIV patients with visceral obesity, but the compound has not progressed to approval. It is sold as a research chemical.
Adipotide and comparison to other peptides
The evidence block does not contain any direct comparisons between Adipotide and other peptides. The review [3] on therapeutic peptides in gerontology discusses mechanisms and applications for healthy aging, but does not mention Adipotide specifically. The review [4] on peptide therapies for musculoskeletal injuries and athletic performance mentions AOD-9604 but not Adipotide. Therefore, no comparative data are available.
CJC-1295 with DAC and comparison to other peptides
The review [1] lists CJC-1295 with DAC alongside other GHRH analogues (sermorelin, tesamorelin, CJC-1295 without DAC) and growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin). It notes that these agents are commonly encountered in clinical practice and online self-administration protocols. However, no head-to-head comparisons or efficacy rankings are provided. The review [4] mentions AOD-9604 but not CJC-1295 with DAC specifically.
Comparison table
| Feature | Adipotide | CJC-1295 with DAC |
|---|---|---|
| Class | Chimeric peptidomimetic | GHRH analogue |
| Mechanism | Prohibitin-targeted apoptosis of white adipose vasculature | GHRH receptor agonist; stimulates GH release |
| Identifiers | Sequence: CKGGRAKDC-GG-D(KLAKLAK)2; MW ~3.5 kDa (not specified in evidence) | Not specified in evidence |
| Clinical trials | None listed | Phase 2 in HIV visceral obesity [6] |
| Approval status | Not approved | Not approved |
| Purity data | Not specified | Not specified |
| Safety data | None in evidence | Safety objectives in [6], results not reported |
Where the evidence is stronger
The evidence for CJC-1295 with DAC includes a registered Phase 2 clinical trial [6] in a defined population (HIV patients with visceral obesity). This provides a structured protocol and a clinical context, although the results are not reported in the evidence block. For Adipotide, no clinical trials are listed, and the evidence is limited to mechanistic descriptions without specific study results. Therefore, the published work on CJC-1295 with DAC has a clearer clinical footprint, while Adipotide remains preclinical in the available evidence.
What is simply not known
For both compounds, the evidence block does not provide efficacy outcomes, safety data, or pharmacokinetic parameters. The purity and abundance of gray market preparations are variable [2], but specific data for these two compounds are not given. No head-to-head studies compare Adipotide and CJC-1295 with DAC. The long-term effects, optimal dosing, and risk profiles in humans are unknown. The regulatory status is unapproved for both.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
- [2] Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
- [3] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
- [4] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- [6] A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
- [7] Peptide Supplements and Their Therapeutic Applications in Sports Medicine
- [8] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
- [9] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- [10] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review